.Pharmacolibrary.Drugs.ATC.A.A04AA02_1 .Pharmacolibrary.Drugs.ATC.A.A04AA02_1| name: | Granisetron_1 |
| ATC code: | A04AA02_1 | route: | oral |
| n-compartments | 2 |
Granisetron is a selective 5-HT3 receptor antagonist used primarily as an antiemetic to prevent nausea and vomiting caused by cancer chemotherapy, radiation therapy, and, to a lesser extent, postoperatively. It is an FDA-approved drug and is used clinically worldwide.
Pharmacokinetic parameters for healthy adult volunteers after oral administration of single 2 mg dose (film-coated tablet).
Howell, J, et al., & Gill, D (2009). Pharmacokinetics of a granisetron transdermal system for the treatment of chemotherapy-induced nausea and vomiting. Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners 15(4) 223–231. DOI:10.1177/1078155209104063 PUBMED:https://pubmed.ncbi.nlm.nih.gov/19304880
Fox-Geiman, MP, et al., & Stiff, P (2001). Double-blind comparative trial of oral ondansetron versus oral granisetron versus IV ondansetron in the prevention of nausea and vomiting associated with highly emetogenic preparative regimens prior to stem cell transplantation. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 7(11) 596–603. DOI:10.1053/bbmt.2001.v7.pm11760147 PUBMED:https://pubmed.ncbi.nlm.nih.gov/11760147
Nakade, S, et al., & Miyata, Y (2008). Population pharmacokinetics of aprepitant and dexamethasone in the prevention of chemotherapy-induced nausea and vomiting. Cancer chemotherapy and pharmacology 63(1) 75–83. DOI:10.1007/s00280-008-0713-y PUBMED:https://pubmed.ncbi.nlm.nih.gov/18317761